Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.40 |
| ▸ | AR | P10275 | 4/20 | 0.40 |
| ▸ | ESR1 | P03372 | 3/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.38 |
| ▸ | IKZF2 | Q9UKS7 | 2/20 | 0.36 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.35 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23051639 | 0.89 | CRBN (0.49) | CRBNARESR1DDB1BRD9 | |
| SCHEMBL20046709 | 0.87 | CRBN (0.43) | CRBNARESR1DDB1IKZF3 | |
| SCHEMBL20046716 | 0.87 | CRBN (0.41) | CRBNARESR1DDB1IKZF3 | |
| SCHEMBL20076137 | 0.81 | CRBN (0.46) | CRBNARESR1DDB1IKZF2 | |
| SCHEMBL20046362 | 0.80 | CRBN (0.59) | CRBNARESR1IKZF2IKZF1 | |
| SCHEMBL21477174 | 0.79 | CRBN (0.58) | CRBNARESR1DDB1BTK | |
| SCHEMBL25502269 | 0.79 | CRBN (0.43) | CRBNARDDB1IKZF3BTK | |
| SCHEMBL22692241 | 0.77 | CRBN (0.43) | CRBNARESR1DDB1IKZF2 | |
| SCHEMBL23051651 | 0.77 | CRBN (0.50) | CRBNARDDB1IKZF3 | |
| SCHEMBL20046406 | 0.77 | CRBN (0.56) | CRBNARESR1DDB1IKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021231927-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-11-18 | — | — | WO | disclosed |